Health Sciences Acquisitions Corporation 2
HSAQ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3% | -3.7% | 520% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.3% | 94.5% | 94.9% | 53.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,359.2% | -2,311.8% | -2,179.8% | -19,118.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,419% | -2,316.1% | -2,160.7% | -18,722.9% |
| EPS | -0.4 | -0.5 | -0.49 | -1.66 |
| % Growth | 20% | -2% | 70.5% | – |
| EPS Diluted | -0.4 | -0.5 | -0.49 | -1.66 |
| Weighted Avg Shares Out | 0 | 0 | 38 | 37 |
| Weighted Avg Shares Out Dil | 0 | 0 | 38 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 9.4% | -2,311.8% | -2,179.8% | -18,611.1% |